相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Hepatic Impairment on the Pharmacokinetics of Levomilnacipran Following a Single Oral Dose of a Levomilnacipran Extended-Release Capsule in Human Participants
Laishun Chen et al.
CLINICAL DRUG INVESTIGATION (2014)
The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
Stuart A. Montgomery et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
Angelo Sambunaris et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
David Bakish et al.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2014)
A Model of Placebo Response in Antidepressant Clinical Trials
Bret R. Rutherford et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
Rajnish Mago et al.
CLINICAL DRUG INVESTIGATION (2013)
Levomilnacipran SR efficacy in major depressive disorder (MDD) across patient subgroups: pooled analysis of 5 double-blind, placebo-controlled trials
S. Montgomery et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Post hoc analyses of levomilnacipran SR 40, 80, and 120mg on functional outcomes in major depressive disorder
C. Gommoll et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
L. Citrome
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Multi-modality: a new approach for the treatment of major depressive disorder
Elliott Richelson
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
Stuart A. Montgomery et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Gregory M. Asnis et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety
A. L. Auclair et al.
NEUROPHARMACOLOGY (2013)
The Epidemiological Modelling of Major Depressive Disorder: Application for the Global Burden of Disease Study 2010
Alize J. Ferrari et al.
PLOS ONE (2013)
Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010
Alize J. Ferrari et al.
PLOS MEDICINE (2013)
Levomilnacipran in the treatment of major depressive disorder: an analysis of efficacy and safety data from two phase III studies
W. Greenberg et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States
Ronald C. Kessler et al.
INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH (2012)
The Costs of Depression
Ronald C. Kessler
PSYCHIATRIC CLINICS OF NORTH AMERICA (2012)
Prevalence, Treatment, and Control of Depressive Symptoms in the United States: Results from the National Health and Nutrition Examination Survey (NHANES), 2005-2008
Ruth S. Shim et al.
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE (2011)
Stuck in a rut: rethinking depression and its treatment
Paul E. Holtzheimer et al.
TRENDS IN NEUROSCIENCES (2011)
Mechanisms of disease: Major depressive disorder
R. H. Belmaker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
分享论文
